# Alto Neuroscience

Type: Company (ALTO)

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/alto-neuroscience
Canonical HTML page: https://gethealthbrief.com/entity/alto-neuroscience

## Timeline

- **2026-12-01**: Expected Data Readouts — Anticipated primary endpoint results for the ALTO-100 Phase 2b/3 study in MDD.
- **2026-03-23**: $120M Private Placement — CFO Nick Smith announces a major financing round to accelerate late-stage clinical programs.
- **2025-06-15**: Phase 2b Expansion — Company expands clinical trials for ALTO-100 targeting specific biotypes of depression.
- **2024-02-02**: Initial Public Offering — Alto Neuroscience goes public on the NYSE to fund its precision psychiatry platform.

## Recent coverage (1 stories)

### Alto Neuroscience Secures $120M to Advance Precision Psychiatry Pipeline
2026-03-24 00:43:41 · Sentiment: Positive · Impact: 6/10 · Sources: 3

Alto Neuroscience has successfully raised $120 million through a private placement financing to accelerate its clinical-stage pipeline of precision medicines for mental health. Led by CFO Nick Smith, the funding underscores investor confidence in the company's AI-driven approach to identifying biomarkers for psychiatric disorders.
Full story: https://gethealthbrief.com/story/alto-neuroscience-120m-financing-precision-psychiatry

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.